Elizabeth Berry-Kravis is professor of child neurology at Rush University Medical Center in Chicago.
Elizabeth Berry-Kravis
Professor
Rush University Medical Center
From this contributor
Analysis offers new hope for failed fragile X drug
Eye tracking shows that mavoglurant, a once-abandoned experimental drug for fragile X syndrome, enters the brain and boosts social interest, says Elizabeth Berry-Kravis.
Analysis offers new hope for failed fragile X drug
By
Jessica Wright
26 February 2019 | 6 min read
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
A mouse model of fragile X syndrome lacks a key feature of the condition, prompting researchers to look for other ways to test treatments.
Questions for Elizabeth Berry-Kravis: Dodging mouse traps
By
Jessica Wright
24 May 2016 | 6 min read
Questions for Elizabeth Berry-Kravis: Measuring drug effects
Drugs designed to treat fragile X syndrome have yet to show substantial benefits in people. But rather than abandon them, child neurologist Elizabeth Berry-Kravis suggests a new way to measure their effectiveness.
Questions for Elizabeth Berry-Kravis: Measuring drug effects
By
Nicholette Zeliadt
17 February 2015 | 5 min read
Explore more from The Transmitter
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
By
Jill Adams
15 September 2026 | 2 min read
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
By
Katie Moisse
15 September 2026 | 8 min read
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.
By
Paige Miranda
15 September 2026 | 0 min watch